What Are EHL Factor Products for Hemophilia A? Explained

Extended half-life (EHL) factor products are modified versions of the clotting factor VIII (8) replacement therapy. Half-life refers to the approximate time it takes for the amount of factor in your blood to fall by half ^[1]. These modified products are engineered to reduce how quickly your body clears the medication, allowing it to stay active longer ^{[1] [2]}.

For many people with Hemophilia A, switching to an EHL product may reduce the number of intravenous (IV) infusions needed for routine prophylaxis (regular treatment intended to prevent bleeds) while maintaining a factor level that your clinician considers appropriate ^[3].

How Standard EHL Products Work

Many people using standard-half-life factor VIII require infusions every two to three days. First-generation EHL products were developed to extend the factor’s half-life by about 1.5 to 2 times, potentially allowing for twice-weekly or every-few-days dosing ^{[1] [2] [4]}.

They achieve this through structural modifications:

• Fc fusion: Attaching a specific protein fragment (the Fc portion of an antibody) to the factor, which helps the body recycle the factor rather than breaking it down immediately ^[5].
• PEGylation: Adding a polymer called polyethylene glycol (PEG) that acts like a shield, slowing down how quickly the body clears the factor ^[5].

However, these traditional EHL products face a natural ceiling. In the bloodstream, factor VIII binds to a carrier protein called von Willebrand factor (VWF). Because VWF is naturally cleared from the bloodstream at its own set rate, it pulls the attached factor VIII out with it, limiting how long even a modified factor can last ^[6].

Overcoming the VWF Limit: Efanesoctocog Alfa

Recent advancements have led to newer therapies that reduce this dependence on the body’s VWF. A product called efanesoctocog alfa (brand name Altuviiio) uses a unique combination of modifications, including its own small piece of VWF (the D′-D3 fragment) built right in ^[1].

By providing its own VWF fragment, efanesoctocog alfa does not need to bind to your body’s VWF, which partially shields it from the usual clearance process ^[1]. As a result, its half-life is extended to approximately 41 hours in adults ^[7].

Clinical Trial Results

In the XTEND-1 clinical trial—which studied adolescents and adults with severe Hemophilia A who do not have FVIII inhibitors—efanesoctocog alfa was used for routine prophylaxis as a once-weekly dose ^[3].

• Factor Levels: In the study, once-weekly dosing maintained an average factor activity level above 40 IU/dL (roughly 40% of normal) for most of the week, with a trough level (the lowest level right before the next dose) averaging around 15 IU/dL by day 7 ^{[7] [3]}.
• Bleeding Rates: The trial reported a median of zero annualized bleeds for participants on weekly prophylaxis, and 97% of treated bleeding episodes resolved with a single injection ^{[3] [8]}.

It is important to note that these are study averages, not guarantees for every patient. A median of zero bleeds means that half the participants had zero bleeds, but others did experience bleeding ^[3]. Additionally, while approved for once-weekly routine prophylaxis in adults and children, treating an active bleed or managing surgery requires different, clinician-directed dosing ^{[9] [8]}.

Important Safety and Monitoring Considerations

If your hematologist suggests an EHL product, consider the following practical and safety factors:

• Individualized Treatment: Pharmacokinetics (how the body processes a drug) vary from person to person. Factors like age, body weight, and your natural VWF levels can affect how quickly you clear standard EHL products ^{[10] [11]}. Your doctor will use your physical activity level, joint health, and bleeding history to set treatment goals, rather than assuming a “one-size-fits-all” schedule ^[12].
• Risk of Inhibitors: As with any factor replacement, your body can develop inhibitors (immune system antibodies that stop the factor from working) ^[13]. If you experience recurrent breakthrough bleeding or a bleed does not respond to a usual dose, do not just wait for your next scheduled infusion. Contact your hemophilia treatment center, as they may need to test for inhibitors or anti-PEG antibodies ^{[14] [13]}.
• Laboratory Testing Challenges: Standard laboratory tests used to measure factor VIII activity (such as some one-stage or chromogenic assays) can produce highly inaccurate results with EHL products, sometimes significantly overestimating or underestimating your true protection level ^{[15] [16]}. Your hemophilia center must coordinate with the laboratory to ensure they use a specific test validated for your exact product ^[15].
• Allergic Reactions: Any intravenous biologic product carries a risk of allergic reaction. Seek emergency medical care if you experience hives, wheezing, facial swelling, or severe dizziness after an infusion.